View in EDS HTML Full Text PDF Full Text

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.

Saved in:
Bibliographic Details
Title: Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Authors: Karam JA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org., Msaouel P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PMsaouel@mdanderson.org.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Matin SF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zurita AJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah AY; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Marmonti E; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Duose DY; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Soto LMS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Laberiano-Fernandez C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Lozano M; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Abraham A; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Hallin M; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Chin CD; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Olson P, Der-Torossian H; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Yan X; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wood CG; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Source: Nature communications [Nat Commun] 2023 May 10; Vol. 14 (1), pp. 2684. Date of Electronic Publication: 2023 May 10.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37164948
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Karam+JA%22">Karam JA</searchLink>; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Msaouel+P%22">Msaouel P</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PMsaouel@mdanderson.org.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Haymaker+CL%22">Haymaker CL</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Matin+SF%22">Matin SF</searchLink>; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Campbell+MT%22">Campbell MT</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Zurita+AJ%22">Zurita AJ</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Shah+AY%22">Shah AY</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Wistuba+II%22">Wistuba II</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Marmonti+E%22">Marmonti E</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Duose+DY%22">Duose DY</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Parra+ER%22">Parra ER</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Soto+LMS%22">Soto LMS</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Laberiano-Fernandez+C%22">Laberiano-Fernandez C</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Lozano+M%22">Lozano M</searchLink>; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Abraham+A%22">Abraham A</searchLink>; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Hallin+M%22">Hallin M</searchLink>; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Chin+CD%22">Chin CD</searchLink>; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Olson+P%22">Olson P</searchLink><br /><searchLink fieldCode="AU" term="%22Der-Torossian+H%22">Der-Torossian H</searchLink>; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Yan+X%22">Yan X</searchLink>; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Tannir+NM%22">Tannir NM</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Wood+CG%22">Wood CG</searchLink>; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2023 May 10; Vol. 14 (1), pp. 2684. <i>Date of Electronic Publication: </i>2023 May 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37164948
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-023-38342-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2684
    Titles:
      – TitleFull: Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Karam JA
      – PersonEntity:
          Name:
            NameFull: Msaouel P
      – PersonEntity:
          Name:
            NameFull: Haymaker CL
      – PersonEntity:
          Name:
            NameFull: Matin SF
      – PersonEntity:
          Name:
            NameFull: Campbell MT
      – PersonEntity:
          Name:
            NameFull: Zurita AJ
      – PersonEntity:
          Name:
            NameFull: Shah AY
      – PersonEntity:
          Name:
            NameFull: Wistuba II
      – PersonEntity:
          Name:
            NameFull: Marmonti E
      – PersonEntity:
          Name:
            NameFull: Duose DY
      – PersonEntity:
          Name:
            NameFull: Parra ER
      – PersonEntity:
          Name:
            NameFull: Soto LMS
      – PersonEntity:
          Name:
            NameFull: Laberiano-Fernandez C
      – PersonEntity:
          Name:
            NameFull: Lozano M
      – PersonEntity:
          Name:
            NameFull: Abraham A
      – PersonEntity:
          Name:
            NameFull: Hallin M
      – PersonEntity:
          Name:
            NameFull: Chin CD
      – PersonEntity:
          Name:
            NameFull: Olson P
      – PersonEntity:
          Name:
            NameFull: Der-Torossian H
      – PersonEntity:
          Name:
            NameFull: Yan X
      – PersonEntity:
          Name:
            NameFull: Tannir NM
      – PersonEntity:
          Name:
            NameFull: Wood CG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 05
              Text: 2023 May 10
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1